Clinical trial
An Exploratory Non-randomized Controlled Trial for Effect and Safety of Envafolimab Combined With Recombinant Human Endostartin Injection/S-1 in Second-line Treatment of Advanced Non-small Cell Lung Cancer
NCT05529355 is registered in ClinicalTrials.gov with Anhui Chest Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Exploratory Non-randomized Controlled Trial for Effect and Safety of Envafolimab Combined With Recombinant Human Endostartin Injection/S-1 in Second-line Treatment of Advanced Non-small Cell Lung Cancer
- Lead sponsor
- Anhui Chest Hospital
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- September 18, 2022
- Completion date
- September 18, 2023
- Enrollment
- 45 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.